Amita Saggi, PA
Physician Assistant · Pleasanton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Amita Saggi’s office at (650) 723-4000 to ask if they take your plan before you enroll.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$1,690,306
Medicare paid this office $1,690,306 for 322 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 15 | $363,310 | None |
| Injection, denosumab, 1 mg | 30 | $103,823 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 35 | $85,328 | None |
| Return visit (30+ min) | 212 | $44,556 | $99 |
| Administration of chemotherapy into vein, 1 hour or less | 55 | $16,972 | $118 |
See all 24 services
| Injection, pembrolizumab, 1 mg | 15 | $363,310 | None |
| Injection, denosumab, 1 mg | 30 | $103,823 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 35 | $85,328 | None |
| Return visit (30+ min) | 212 | $44,556 | $99 |
| Administration of chemotherapy into vein, 1 hour or less | 55 | $16,972 | $118 |
| Short return visit (20+ min) | 92 | $14,683 | $69 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $11,086 | None |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 12 | $10,942 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13 | $3,543 | $0 |
| Long return visit (40+ min) | 24 | $3,264 | $131 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 159 | $3,159 | $8 |
| Injection of additional new drug or substance into vein | 43 | $2,903 | $13 |
| Injection of drug or substance under skin or into muscle | 85 | $2,806 | $12 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $2,805 | $57 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 28 | $2,155 | $53 |
| Injection of drug or substance into vein | 20 | $1,242 | $33 |
| Administration of chemotherapy into vein, each additional hour | 17 | $1,207 | $24 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $1,009 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 15 | $600 | $25 |
| Injection, palonosetron hcl, 25 mcg | 29 | $413 | None |
| Application of on-body injector for under skin injection | 14 | $378 | $16 |
| Injection, fosaprepitant, 1 mg | 13 | $352 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 32 | $77 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $41 | None |
Who their Medicare patients are
322 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 19% · Women 55% · Also on Medicaid 14% · Health risk score 2.36. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 75% · Chronic kidney disease 48% · Cancer 46% · Diabetes 35% · Coronary heart disease 30% · Depression 23% · Heart failure 22% · COPD 22% · Atrial fibrillation 22% · Stroke 11% · Dementia 8%.
The office billed $8,305,681, Medicare allowed $2,128,090 and paid $1,690,306; for 136,544 services of 100 kinds; $1,581,695 of it was for drugs given in the office and $108,611 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 322 | 136,544 | 77 | 2.36 | $8,305,681 | $1,690,306 |
| 2023 | 460 | 303,681 | 77 | 2.02 | $21,016,373 | $4,455,323 |
| 2022 | 354 | 209,037 | 76 | 2.29 | $10,175,669 | $2,250,452 |
| 2021 | 232 | 91,198 | 77 | 2.57 | $5,605,139 | $1,288,845 |
| 2020 | 307 | 163,413 | 76 | 2.17 | $7,107,310 | $1,557,360 |
| 2019 | 335 | 157,388 | 75 | 2.37 | $5,986,222 | $1,326,363 |
| 2018 | 233 | 167,914 | 75 | 2.49 | $5,112,165 | $1,171,525 |
| 2017 | 216 | 107,514 | 76 | 2.53 | $3,150,335 | $725,402 |
| 2016 | 55 | 7,325 | 75 | 2.00 | $241,549 | $44,013 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 33 services
| Injection, pembrolizumab, 1 mg | 20 | $1,322,862 | None |
| Injection, denosumab, 1 mg | 56 | $280,904 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 42 | $194,944 | None |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 26 | $57,454 | None |
| Administration of chemotherapy into vein, 1 hour or less | 72 | $51,439 | $117 |
| Return visit (30+ min) | 230 | $45,296 | $94 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 34 | $27,712 | None |
| Short return visit (20+ min) | 147 | $27,640 | $70 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $9,981 | $57 |
| Injection of additional new drug or substance into vein | 61 | $9,050 | $13 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 302 | $8,679 | $8 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 20 | $7,247 | $0 |
| Injection of drug or substance under skin or into muscle | 120 | $5,770 | $12 |
| Long return visit (40+ min) | 34 | $4,779 | $137 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 42 | $4,279 | $55 |
| Administration of chemotherapy into vein, each additional hour | 24 | $4,099 | $24 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 41 | $2,847 | $30 |
| Administration of additional new drug or substance into vein using push technique | 14 | $2,796 | $49 |
| Drawing of blood for a medical problem | 15 | $2,427 | $84 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 22 | $2,245 | $25 |
| Injection, fosaprepitant, 1 mg | 20 | $1,522 | None |
| Injection, palonosetron hcl, 25 mcg | 41 | $1,507 | None |
| Injection of drug or substance into vein | 29 | $1,379 | $33 |
| Injection, paclitaxel, 1 mg | 12 | $1,111 | None |
| Application of on-body injector for under skin injection | 25 | $929 | $16 |
| Injection, carboplatin, 50 mg | 16 | $722 | None |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $719 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $719 | $18 |
| Injection, zoledronic acid, 1 mg | 13 | $580 | None |
| Infusion into a vein for hydration, each additional hour | 11 | $352 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 49 | $248 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 51 | $165 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $66 | None |
2022: 30 services
| Injection, pembrolizumab, 1 mg | 13 | $472,412 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 30 | $143,564 | None |
| Injection, denosumab, 1 mg | 35 | $125,610 | None |
| Return visit (30+ min) | 197 | $52,293 | $99 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 19 | $48,217 | None |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 14 | $30,460 | None |
| Administration of chemotherapy into vein, 1 hour or less | 57 | $26,885 | $122 |
| Short return visit (20+ min) | 59 | $14,070 | $69 |
| Administration of additional new drug or substance into vein, 1 hour or less | 28 | $7,119 | $59 |
| Long return visit (40+ min) | 37 | $6,456 | $150 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $5,989 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 219 | $5,894 | $8 |
| Injection of additional new drug or substance into vein | 58 | $5,792 | $14 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 12 | $5,594 | $147 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $4,888 | $1 |
| Injection of drug or substance under skin or into muscle | 84 | $4,424 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | $3,164 | $58 |
| Administration of additional new drug or substance into vein using push technique | 16 | $2,933 | $51 |
| Administration of chemotherapy into vein, each additional hour | 25 | $2,803 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 20 | $1,508 | $26 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $1,145 | $29 |
| Insertion of needle into vein for collection of blood sample | 139 | $1,132 | $3 |
| Injection, palonosetron hcl, 25 mcg | 35 | $1,068 | None |
| Injection of drug or substance into vein | 19 | $822 | $34 |
| Injection, fosaprepitant, 1 mg | 16 | $749 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $625 | $18 |
| Injection, fluorouracil, 500 mg | 12 | $561 | None |
| Application of on-body injector for under skin injection | 16 | $466 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 42 | $151 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 42 | $107 | None |
2021: 19 services
| Injection, pembrolizumab, 1 mg | 13 | $315,489 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 25 | $68,982 | None |
| Injection, denosumab, 1 mg | 23 | $61,329 | None |
| Return visit (30+ min) | 149 | $24,921 | $100 |
| Administration of chemotherapy into vein, 1 hour or less | 49 | $16,284 | $129 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 13 | $15,704 | None |
| Short return visit (20+ min) | 55 | $6,518 | $63 |
| Long return visit (40+ min) | 30 | $5,022 | $167 |
| Injection of additional new drug or substance into vein | 41 | $2,874 | $14 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 123 | $2,463 | $8 |
| Administration of additional new drug or substance into vein, 1 hour or less | 21 | $2,425 | $64 |
| Injection of drug or substance under skin or into muscle | 64 | $1,604 | $11 |
| Administration of additional new drug or substance into vein using push technique | 13 | $1,579 | $51 |
| Injection, palonosetron hcl, 25 mcg | 28 | $1,120 | None |
| Insertion of needle into vein for collection of blood sample | 116 | $861 | $3 |
| Administration of chemotherapy into vein, each additional hour | 13 | $790 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 12 | $446 | $28 |
| Injection, dexamethasone sodium phosphate, 1 mg | 27 | $64 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 26 | $40 | None |
2020: 27 services
| Injection, pembrolizumab, 1 mg | 15 | $329,598 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 35 | $164,655 | None |
| Injection, denosumab, 1 mg | 37 | $147,777 | None |
| Injection, pegfilgrastim, 6 mg | 13 | $74,486 | None |
| Return visit (30+ min) | 228 | $53,635 | $85 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 21 | $40,390 | None |
| Short return visit (20+ min) | 140 | $25,610 | $59 |
| Administration of chemotherapy into vein, 1 hour or less | 54 | $18,889 | $126 |
| Long return visit (40+ min) | 45 | $5,888 | $125 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 194 | $5,552 | $8 |
| Injection of additional new drug or substance into vein | 49 | $3,967 | $14 |
| Injection of drug or substance under skin or into muscle | 101 | $3,912 | $11 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 11 | $3,778 | $145 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $3,104 | $61 |
| Administration of additional new drug or substance into vein using push technique | 17 | $2,672 | $51 |
| Injection, palonosetron hcl, 25 mcg | 34 | $2,417 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $2,028 | $63 |
| Insertion of needle into vein for collection of blood sample | 185 | $1,953 | $3 |
| Administration of chemotherapy into vein, each additional hour | 18 | $1,428 | $26 |
| Irrigation of implanted venous access drug delivery device | 15 | $627 | $25 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $493 | $27 |
| Injection of drug or substance into vein | 13 | $491 | $33 |
| Injection, fluorouracil, 500 mg | 11 | $334 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 37 | $89 | None |
| Infusion, normal saline solution , 1000 cc | 15 | $47 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $45 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $44 | None |
2019: 32 services
| Injection, pembrolizumab, 1 mg | 16 | $308,961 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 28 | $133,775 | None |
| Injection, rituximab, 10 mg | 12 | $128,988 | None |
| Injection, denosumab, 1 mg | 38 | $112,255 | None |
| Return visit (30+ min) | 273 | $50,640 | $85 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 16 | $22,280 | None |
| Administration of chemotherapy into vein, 1 hour or less | 61 | $20,766 | $124 |
| Short return visit (20+ min) | 129 | $18,590 | $58 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 26 | $11,119 | $1 |
| Injection, palonosetron hcl, 25 mcg | 30 | $8,307 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 282 | $6,847 | $8 |
| Injection of drug or substance under skin or into muscle | 109 | $5,446 | $13 |
| Long return visit (40+ min) | 30 | $3,491 | $113 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $3,425 | $60 |
| Injection of additional new drug or substance into vein | 47 | $3,300 | $14 |
| Administration of chemotherapy into vein, each additional hour | 28 | $2,680 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 34 | $2,612 | $26 |
| Administration of additional new drug or substance into vein using push technique | 15 | $2,013 | $49 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 13 | $1,971 | None |
| Infusion into a vein for hydration, 31-60 minutes | 24 | $1,727 | $33 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 17 | $1,456 | $61 |
| Injection of drug or substance into vein | 29 | $1,160 | $33 |
| Insertion of needle into vein for collection of blood sample | 204 | $988 | $3 |
| Injection, oxaliplatin, 0.5 mg | 11 | $964 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $647 | $26 |
| Injection, fluorouracil, 500 mg | 15 | $584 | None |
| Injection, ranitidine hydrochloride, 25 mg | 26 | $401 | None |
| Infusion into a vein for hydration, each additional hour | 12 | $335 | $12 |
| Infusion, normal saline solution , 1000 cc | 23 | $114 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 44 | $103 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 16 | $59 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 28 | $29 | None |
2018: 32 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 31 | $114,588 | None |
| Injection, pegfilgrastim, 6 mg | 13 | $68,436 | None |
| Injection, denosumab, 1 mg | 24 | $55,745 | None |
| Return visit (30+ min) | 162 | $34,946 | $84 |
| Injection, ferric carboxymaltose, 1 mg | 34 | $29,240 | None |
| Administration of chemotherapy into vein, 1 hour or less | 63 | $23,103 | $124 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 19 | $21,653 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 11 | $17,666 | None |
| Injection, palonosetron hcl, 25 mcg | 39 | $17,064 | None |
| Short return visit (20+ min) | 94 | $15,177 | $56 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 183 | $6,627 | $9 |
| Injection of drug or substance under skin or into muscle | 99 | $5,229 | $17 |
| Injection of additional new drug or substance into vein | 64 | $4,681 | $15 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 15 | $4,321 | None |
| Administration of additional new drug or substance into vein using push technique | 24 | $3,806 | $51 |
| Long return visit (40+ min) | 34 | $3,753 | $110 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 42 | $3,305 | $27 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $2,902 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 17 | $2,344 | $63 |
| Administration of chemotherapy into vein, each additional hour | 28 | $2,217 | $26 |
| Injection of drug or substance into vein | 36 | $2,167 | $39 |
| Infusion into a vein for hydration, 31-60 minutes | 20 | $1,742 | $40 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $1,527 | None |
| Injection, oxaliplatin, 0.5 mg | 14 | $1,486 | None |
| Injection, fluorouracil, 500 mg | 15 | $682 | None |
| Injection, carboplatin, 50 mg | 16 | $512 | None |
| Irrigation of implanted venous access drug delivery device | 11 | $397 | $23 |
| Injection, ranitidine hydrochloride, 25 mg | 26 | $373 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 53 | $142 | None |
| Infusion, normal saline solution , 1000 cc | 20 | $68 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $59 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 43 | $46 | None |
2017: 29 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 28 | $68,642 | None |
| Injection, denosumab, 1 mg | 19 | $38,991 | None |
| Injection, ferric carboxymaltose, 1 mg | 22 | $23,039 | None |
| Short return visit (20+ min) | 144 | $22,032 | $55 |
| Return visit (30+ min) | 112 | $18,234 | $83 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 18 | $18,040 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $13,240 | None |
| Administration of chemotherapy into vein, 1 hour or less | 50 | $12,535 | $117 |
| Injection, palonosetron hcl, 25 mcg | 25 | $7,832 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 179 | $5,716 | $10 |
| Injection of drug or substance under skin or into muscle | 93 | $4,485 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 46 | $3,903 | $25 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $2,894 | $60 |
| Injection of drug or substance into vein | 27 | $2,174 | $48 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $1,984 | $58 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $1,868 | $55 |
| Infusion into a vein for hydration, 31-60 minutes | 17 | $1,857 | $49 |
| Injection of additional new drug or substance into vein | 37 | $1,555 | $19 |
| Long return visit (40+ min) | 12 | $1,229 | $102 |
| Administration of chemotherapy into vein, each additional hour | 16 | $1,049 | $23 |
| Administration of additional new drug or substance into vein using push technique | 11 | $893 | $53 |
| Injection, carboplatin, 50 mg | 11 | $386 | None |
| Infusion into a vein for hydration, each additional hour | 11 | $315 | $13 |
| Insertion of needle into vein for collection of blood sample | 22 | $91 | $3 |
| Infusion, normal saline solution , 1000 cc | 19 | $76 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 39 | $70 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 16 | $66 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 37 | $37 | None |
| Not otherwise classified, antineoplastic drugs | 23 | $21 | None |
2016: 5 services
| Short return visit (20+ min) | 36 | $2,784 | $56 |
| Return visit (30+ min) | 14 | $1,145 | $82 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 33 | $426 | $10 |
| Injection of drug or substance under skin or into muscle | 16 | $386 | $20 |
| Insertion of needle into vein for collection of blood sample | 16 | $53 | $3 |
Drugs they prescribed that Part D paid
$4,290,893
Pharmacies billed $4,290,893 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (23 of 1,240) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
902 generic and 338 brand-name prescriptions · $4,290,893 in drug cost · 15 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | 33 | $647,567 | $19,623 |
| Abiraterone Acetate | 152 | $586,934 | $3,861 |
| Revlimid | 34 | $534,428 | $15,718 |
| Brukinsa | 30 | $454,300 | $15,143 |
| Tagrisso | 19 | $327,112 | $17,216 |
See all 29 drugs
| Jakafi | 33 | $647,567 | $19,623 |
| Abiraterone Acetate | 152 | $586,934 | $3,861 |
| Revlimid | 34 | $534,428 | $15,718 |
| Brukinsa | 30 | $454,300 | $15,143 |
| Tagrisso | 19 | $327,112 | $17,216 |
| Welireg | 11 | $262,206 | $23,837 |
| Lynparza | 18 | $223,340 | $12,408 |
| Imbruvica | 13 | $188,008 | $14,462 |
| Lenalidomide | 20 | $187,155 | $9,358 |
| Ninlaro | 12 | $151,424 | $12,619 |
| Xarelto | 60 | $77,156 | $1,286 |
| Eliquis | 47 | $35,658 | $759 |
| Imatinib Mesylate | 13 | $10,602 | $816 |
| Letrozole | 100 | $2,876 | $29 |
| Hydroxyurea | 30 | $662 | $22 |
| Mirtazapine | 27 | $459 | $17 |
| Dexamethasone | 21 | $427 | $20 |
| Prednisone | 78 | $377 | $5 |
| Tamoxifen Citrate | 22 | $366 | $17 |
| Ondansetron | 32 | $357 | $11 |
| Allopurinol | 47 | $347 | $7 |
| Prochlorperazine Maleate | 34 | $309 | $9 |
| Alendronate | 22 | $251 | $11 |
| Omeprazole | 28 | $223 | $8 |
| Lidocaine-Prilocaine | 15 | $189 | $13 |
| Acyclovir | 13 | $143 | $11 |
| Gabapentin | 23 | $125 | $5 |
| Warfarin | 11 | $76 | $7 |
| Potassium Chloride | 15 | $21 | $1 |
Year by year
| 2024 | 1,240 | 246 | 2% (23) | 27% | $4,290,893 |
| 2023 | 1,334 | 263 | 2% (30) | None | $4,731,693 |
| 2022 | 955 | 213 | 7% (64) | None | $2,913,924 |
| 2021 | 793 | 197 | 4% (32) | 30% | $2,078,628 |
| 2020 | 1,292 | 237 | 5% (62) | 25% | $3,164,110 |
| 2019 | 761 | 179 | 5% (35) | 18% | $876,020 |
| 2018 | 758 | 135 | 11% (85) | 15% | $341,108 |
| 2017 | 680 | 122 | 8% (52) | 10% | $183,366 |
| 2016 | 483 | 101 | 12% (59) | 12% | $99,113 |
| 2015 | 317 | 51 | 8% (24) | None | $61,023 |
| 2014 | 326 | 54 | 8% (26) | None | $8,184 |
| 2013 | 65 | 21 | 17% (11) | None | $3,296 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 38 drugs
| Revlimid | 61 | $1,007,400 | $16,515 |
| Imbruvica | 29 | $474,159 | $16,350 |
| Abiraterone Acetate | 81 | $443,977 | $5,481 |
| Jakafi | 32 | $437,791 | $13,681 |
| Verzenio | 20 | $322,933 | $16,147 |
| Tagrisso | 17 | $290,703 | $17,100 |
| Lenalidomide | 16 | $202,101 | $12,631 |
| Xtandi | 13 | $194,376 | $14,952 |
| Sutent | 13 | $145,413 | $11,186 |
| Xarelto | 81 | $101,784 | $1,257 |
| Calquence | 11 | $79,573 | $7,234 |
| Creon | 26 | $44,196 | $1,700 |
| Eliquis | 38 | $27,643 | $727 |
| Imatinib Mesylate | 17 | $21,657 | $1,274 |
| Letrozole | 99 | $4,560 | $46 |
| Anagrelide | 16 | $3,250 | $203 |
| Ondansetron | 50 | $1,040 | $21 |
| Hydroxyurea | 39 | $1,023 | $26 |
| Venlafaxine Hcl Er | 22 | $633 | $29 |
| Allopurinol | 43 | $560 | $13 |
| Acyclovir | 13 | $502 | $39 |
| Tamoxifen Citrate | 22 | $484 | $22 |
| Hydrocodone-Acetaminophen | 17 | $462 | $27 |
| Lidocaine-Prilocaine | 25 | $406 | $16 |
| Mirtazapine | 16 | $391 | $24 |
| Potassium Chloride | 26 | $373 | $14 |
| Dexamethasone | 27 | $372 | $14 |
| Prochlorperazine Maleate | 44 | $344 | $8 |
| Anastrozole | 13 | $315 | $24 |
| Prednisone | 38 | $290 | $8 |
| Alendronate | 18 | $265 | $15 |
| Gabapentin | 15 | $200 | $13 |
| Omeprazole | 20 | $199 | $10 |
| Levothyroxine | 23 | $186 | $8 |
| Tamsulosin | 11 | $139 | $13 |
| Warfarin | 17 | $98 | $6 |
| Folic Acid | 22 | $80 | $4 |
| Zolpidem Tartrate Er | 13 | $78 | $6 |
2022: 28 drugs
| Imbruvica | 45 | $698,712 | $15,527 |
| Revlimid | 37 | $595,036 | $16,082 |
| Xtandi | 31 | $447,515 | $14,436 |
| Jakafi | 19 | $312,255 | $16,434 |
| Abiraterone Acetate | 26 | $138,634 | $5,332 |
| Venclexta | 19 | $124,212 | $6,537 |
| Xarelto | 47 | $51,485 | $1,095 |
| Creon | 15 | $12,854 | $857 |
| Eliquis | 13 | $10,194 | $784 |
| Letrozole | 57 | $1,688 | $30 |
| Ondansetron | 61 | $1,363 | $22 |
| Hydrocodone-Acetaminophen | 26 | $1,296 | $50 |
| Hydroxyurea | 36 | $965 | $27 |
| Tamoxifen Citrate | 23 | $706 | $31 |
| Morphine Sulfate Er | 17 | $623 | $37 |
| Prochlorperazine Maleate | 47 | $569 | $12 |
| Venlafaxine Hcl Er | 22 | $490 | $22 |
| Dexamethasone | 16 | $484 | $30 |
| Allopurinol | 37 | $454 | $12 |
| Anastrozole | 14 | $343 | $25 |
| Pantoprazole | 11 | $313 | $28 |
| Lidocaine-Prilocaine | 17 | $258 | $15 |
| Prednisone | 31 | $239 | $8 |
| Levothyroxine | 12 | $190 | $16 |
| Alendronate | 11 | $180 | $16 |
| Mirtazapine | 12 | $121 | $10 |
| Folic Acid | 13 | $88 | $7 |
| Warfarin | 14 | $63 | $5 |
2021: 23 drugs
| Revlimid | 42 | $665,200 | $15,838 |
| Imbruvica | 25 | $462,970 | $18,519 |
| Xtandi | 22 | $272,995 | $12,409 |
| Xarelto | 64 | $54,643 | $854 |
| Eliquis | 11 | $7,619 | $693 |
| Letrozole | 64 | $2,289 | $36 |
| Tamoxifen Citrate | 39 | $1,442 | $37 |
| Hydroxyurea | 35 | $1,088 | $31 |
| Acyclovir | 31 | $1,009 | $33 |
| Anastrozole | 25 | $1,003 | $40 |
| Ondansetron | 42 | $835 | $20 |
| Dexamethasone | 20 | $634 | $32 |
| Prochlorperazine Maleate | 45 | $415 | $9 |
| Mirtazapine | 14 | $377 | $27 |
| Lidocaine-Prilocaine | 17 | $286 | $17 |
| Hydrocodone-Acetaminophen | 14 | $284 | $20 |
| Omeprazole | 15 | $281 | $19 |
| Allopurinol | 19 | $270 | $14 |
| Pantoprazole | 15 | $229 | $15 |
| Venlafaxine Hcl Er | 14 | $186 | $13 |
| Alendronate | 16 | $163 | $10 |
| Escitalopram | 12 | $129 | $11 |
| Tramadol | 12 | $19 | $2 |
2020: 33 drugs
| Imbruvica | 41 | $829,678 | $20,236 |
| Revlimid | 51 | $705,917 | $13,842 |
| Xtandi | 25 | $293,573 | $11,743 |
| Tagrisso | 16 | $257,171 | $16,073 |
| Ninlaro | 15 | $155,770 | $10,385 |
| Sutent | 12 | $121,327 | $10,111 |
| Lonsurf | 12 | $80,938 | $6,745 |
| Xarelto | 49 | $36,169 | $738 |
| Eliquis | 12 | $8,059 | $672 |
| Exemestane | 18 | $6,907 | $384 |
| Tamoxifen Citrate | 39 | $4,264 | $109 |
| Letrozole | 89 | $2,790 | $31 |
| Hydroxyurea | 43 | $1,976 | $46 |
| Ondansetron | 105 | $1,956 | $19 |
| Anastrozole | 40 | $1,433 | $36 |
| Prochlorperazine Maleate | 98 | $1,305 | $13 |
| Dexamethasone | 47 | $1,130 | $24 |
| Acyclovir | 34 | $873 | $26 |
| Bupropion Xl | 12 | $671 | $56 |
| Doxycycline Hyclate | 14 | $649 | $46 |
| Lidocaine-Prilocaine | 31 | $556 | $18 |
| Pantoprazole | 19 | $437 | $23 |
| Hydrocodone-Acetaminophen | 33 | $397 | $12 |
| Mirtazapine | 12 | $378 | $32 |
| Omeprazole | 22 | $352 | $16 |
| Alendronate | 27 | $297 | $11 |
| Warfarin | 12 | $266 | $22 |
| Allopurinol | 27 | $253 | $9 |
| Escitalopram | 26 | $217 | $8 |
| Prednisone | 24 | $175 | $7 |
| Lorazepam | 21 | $100 | $5 |
| Tramadol | 16 | $44 | $3 |
| Potassium Chloride | 11 | $29 | $3 |
2019: 23 drugs
| Imbruvica | 19 | $295,059 | $15,529 |
| Revlimid | 17 | $199,280 | $11,722 |
| Xtandi | 11 | $132,233 | $12,021 |
| Xarelto | 36 | $27,387 | $761 |
| Exemestane | 14 | $4,121 | $294 |
| Tamoxifen Citrate | 19 | $2,084 | $110 |
| Ondansetron | 81 | $1,822 | $22 |
| Letrozole | 65 | $1,629 | $25 |
| Hydroxyurea | 21 | $1,121 | $53 |
| Dexamethasone | 32 | $776 | $24 |
| Anastrozole | 20 | $726 | $36 |
| Prochlorperazine Maleate | 52 | $510 | $10 |
| Hydrocodone-Acetaminophen | 27 | $444 | $16 |
| Lidocaine-Prilocaine | 23 | $397 | $17 |
| Acyclovir | 22 | $363 | $16 |
| Ondansetron Odt | 11 | $336 | $31 |
| Omeprazole | 31 | $297 | $10 |
| Alendronate | 19 | $217 | $11 |
| Venlafaxine Hcl Er | 11 | $207 | $19 |
| Escitalopram | 26 | $187 | $7 |
| Allopurinol | 12 | $157 | $13 |
| Lorazepam | 18 | $130 | $7 |
| Prednisone | 13 | $77 | $6 |
2018: 22 drugs
| Imbruvica | 13 | $162,262 | $12,482 |
| Xarelto | 17 | $16,509 | $971 |
| Ondansetron | 80 | $1,559 | $19 |
| Tamoxifen Citrate | 20 | $1,308 | $65 |
| Letrozole | 45 | $582 | $13 |
| Dexamethasone | 22 | $566 | $26 |
| Morphine Sulfate Er | 19 | $500 | $26 |
| Acyclovir | 27 | $466 | $17 |
| Lidocaine-Prilocaine | 24 | $466 | $19 |
| Anastrozole | 28 | $384 | $14 |
| Oxycodone | 12 | $382 | $32 |
| Hydrocodone-Acetaminophen | 27 | $346 | $13 |
| Prochlorperazine Maleate | 51 | $295 | $6 |
| Potassium Chloride | 16 | $284 | $18 |
| Lorazepam | 45 | $219 | $5 |
| Levofloxacin | 11 | $190 | $17 |
| Allopurinol | 25 | $148 | $6 |
| Omeprazole | 16 | $143 | $9 |
| Escitalopram | 20 | $135 | $7 |
| Prednisone | 15 | $120 | $8 |
| Venlafaxine Hcl Er | 11 | $107 | $10 |
| Furosemide | 22 | $40 | $2 |
2017: 16 drugs
| Promacta | 14 | $85,692 | $6,121 |
| Ondansetron | 63 | $1,009 | $16 |
| Letrozole | 31 | $434 | $14 |
| Lidocaine-Prilocaine | 17 | $420 | $25 |
| Anastrozole | 30 | $381 | $13 |
| Hydrocodone-Acetaminophen | 17 | $381 | $22 |
| Dexamethasone | 43 | $374 | $9 |
| Acyclovir | 28 | $355 | $13 |
| Levofloxacin | 25 | $331 | $13 |
| Lorazepam | 70 | $329 | $5 |
| Potassium Chloride | 19 | $320 | $17 |
| Lidocaine Hcl Viscous | 12 | $285 | $24 |
| Prochlorperazine Maleate | 49 | $241 | $5 |
| Mirtazapine | 14 | $133 | $9 |
| Gabapentin | 14 | $54 | $4 |
| Tramadol | 12 | $43 | $4 |
2016: 12 drugs
| Ondansetron | 30 | $654 | $22 |
| Oxycodone-Acetaminophen | 11 | $546 | $50 |
| Hydrocodone-Acetaminophen | 18 | $414 | $23 |
| Acyclovir | 25 | $358 | $14 |
| Lidocaine-Prilocaine | 14 | $356 | $25 |
| Dexamethasone | 25 | $283 | $11 |
| Potassium Chloride | 12 | $232 | $19 |
| Lorazepam | 39 | $191 | $5 |
| Prochlorperazine Maleate | 25 | $148 | $6 |
| Omeprazole | 15 | $112 | $7 |
| Tramadol | 13 | $53 | $4 |
| Furosemide | 11 | $22 | $2 |
2015: 11 drugs
| Potassium Chloride | 21 | $1,142 | $54 |
| Hydrocodone-Acetaminophen | 16 | $811 | $51 |
| Zolpidem | 13 | $317 | $24 |
| Omeprazole | 33 | $317 | $10 |
| Dexamethasone | 20 | $274 | $14 |
| Prednisone | 16 | $246 | $15 |
| Acyclovir | 15 | $211 | $14 |
| Ondansetron | 15 | $181 | $12 |
| Lorazepam | 22 | $95 | $4 |
| Prochlorperazine Maleate | 21 | $87 | $4 |
| Furosemide | 17 | $77 | $5 |
2014: 10 drugs
| Potassium Chloride | 21 | $805 | $38 |
| Ondansetron | 24 | $365 | $15 |
| Lidocaine-Prilocaine | 13 | $334 | $26 |
| Prochlorperazine Maleate | 23 | $256 | $11 |
| Hydrocodone-Acetaminophen | 13 | $253 | $19 |
| Lorazepam | 33 | $155 | $5 |
| Omeprazole | 14 | $143 | $10 |
| Prednisone | 12 | $115 | $10 |
| Zolpidem | 11 | $88 | $8 |
| Furosemide | 18 | $78 | $4 |
Money from drug and device companies
$188 in 2025
| 2025 | 5 | 7 | None | $188 |
| 2024 | 12 | 21 | None | $509 |
| 2023 | 11 | 34 | None | $740 |
| 2022 | 7 | 8 | None | $197 |
| 2021 | 2 | 6 | None | $148 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Takeda Pharmaceuticals U.S.A. | Iclusig | $56 | 2 payments
|
| Daiichi Sankyo | Enhertu | $51 | 2 payments
|
| Abbvie | Imbruvica | $28 | 1 payment
|
| Gilead Sciences | Trodelvy | $27 | 1 payment
|
| Teleflex | Arrow | $25 | 1 payment
|
See all 7 published payments
| Abbvie | Meals · 2025-12-04 | Imbruvica | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-25 | Iclusig | $30 |
| Gilead Sciences | Meals · 2025-10-23 | Trodelvy | $27 |
| Teleflex | Meals · 2025-06-25 | Arrow | $25 |
| Daiichi Sankyo | Meals · 2025-06-11 | Enhertu | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-22 | Iclusig | $26 |
| Daiichi Sankyo | Meals · 2025-05-06 | Enhertu | $27 |
See earlier years (2024, 2023, 2022, 2021)
2024: $509
| Daiichi Sankyo | Enhertu | $177 | 7 payments
|
| Janssen Biotech | Erleada | $60 | 2 payments
|
| Eisai | Lenvima | $42 | 2 payments
|
| Gilead Sciences | None | $40 | 2 payments
|
| Rigel Pharmaceuticals | Rezlidhia | $29 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $28 | 1 payment
|
| Celgene | Pomalyst | $26 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $26 | 1 payment
|
| Pfizer | Inlyta | $25 | 1 payment
|
| BeiGene USA | Brukinsa | $21 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $20 | 1 payment
|
| Novocure | Optune | $15 | 1 payment
|
2023: $740
| Daiichi Sankyo | Injectafer | $171 | 10 payments
|
| Pfizer | Ibrance | $143 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $125 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $90 | 3 payments
|
| Amgen | Evenity | $69 | 3 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $46 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $23 | 1 payment
|
| Sobi | Doptelet | $20 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $19 | 1 payment
|
| Incyte | Jakafi | $17 | 1 payment
|
| Coherus Biosciences | Udenyca | $16 | 1 payment
|
2022: $197
| E.R. Squibb & Sons L.L.C. | None | $47 | 2 payments
|
| GlaxoSmithKline | Blenrep | $35 | 1 payment
|
| Daiichi Sankyo | Injectafer | $30 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $27 | 1 payment
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $23 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $18 | 1 payment
|
| Novartis Pharmaceuticals | Mekinist | $17 | 1 payment
|
2021: $148
| Pfizer | Inlyta | $93 | 5 payments
|
| Amgen | None | $55 | 1 payment
|
Professional record
- NPI
- 1346580503
- Licence
- CA PA22690
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X); Physician assistant, medical (363AM0700X)
- Mailing address
- 5725 W Las Positas Blvd, Ste 100, Pleasanton, CA, 94588
- NPI first listed
- 2013-02-26
- NPI last updated
- 2024-08-20
- NPI record certified
- 2024-08-20
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 6155 Stoneridge Dr, Pleasanton, CA, 94588